MedWatch

Divestment of new discovery to finance Scandion Oncology's work with cancer asset

The listed Saniona spinout company Scandion Oncology has applied for a patent on a potential competitor and supplement to known antibiotics, but the company has no ambitions to bring the asset to the market itself.

Nils Brünner, co-founder and CEO Scandion Oncology.

Drug candidate SCO-101 is currently the absolute star in Danish Scandion Oncology, and not even the discovery of a new treatment against antibiotic-resistant bacterial infections can change that.

That is the realization in the nearly two-year-old company after preclinical results have shown that the company has a substance in its portfolio, which has proven capable of combatting the otherwise antibiotic-resistant bacterial infections MRSA and VRE – both as a stand-alone treatment and supplemental treatment to certain antibiotics.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier